Carisma Therapeutics Inc (CARM) Actualités

Carmila : Evolution de la composition du Conseil d’administration suite au changement de représentant permanent de la société PREDICA

Regulatory News : La société PREDICA, Administrateur de Carmila (Paris:CARM), a suivant décision du 17 février 2025, nommé en qualité de nouveau...

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference PR...

Carmila: Lancement d’un programme de rachat d’actions pour 10 millions d’euros

Regulatory News: Carmila (Paris:CARM) a confié à un prestataire de service d’investissement un mandat de rachat d’actions au comptant portant sur...

Carmila: 2024 Annual Results: Sustained Growth Driven by the Acquisition of Galimmo and Strong Leasing Momentum

Regulatory News: Carmila (Paris:CARM): Acquisition of Galimmo completed on 1 July 2024 Total investment of €300 million at a 38% discount to EPRA...

Carmila: Information Concerning the Total Number of Voting Rights and Share

Provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement général de...

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference PR...

Form 4 - Statement of changes in beneficial ownership of securities

Carmila: Resources Devoted to the Liquidity Contract as of 31 December 2024

Regulatory News: At 31 December 2024, resources made available for the liquidity agreement concluded by Carmila (Paris:CARM) with Kepler Chevreux...

Form 8-K - Current report

Form 8-K - Current report